20多年来多发性骨髓瘤患者生存率的演变:来自中等水平医院的现实世界经验
Esther Ortega-Vida1, Abel Rosado-Rodriguez1, Rocio Fe1
1Department of Hematology, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain.
Cancers
|March 13, 2025
概括
多发性骨髓瘤 (MM) 治疗的进步在二十年内显著改善了患者的生存率. 新型疗法和自身干细胞移植 (ASCT) 是这一进步的关键驱动力,尽管公平的获取仍然至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床医学 临床医学
背景情况:
- 多发性骨髓瘤 (MM) 治疗格局随着许多治疗进展而发展.
- 这些进展有助于显著改善MM患者的整体存活率 (OS).
- 该研究的重点是评估MM的生存趋势在相当长的时间内.
研究的目的:
- 分析治疗进步对多发性骨髓瘤 (MM) 患者整体存活时间 (OS) 的影响.
- 为了比较不同治疗时期和不同患者群体的生存结果 (移植资格与非资格).
- 评估新药类与传统化疗在MM治疗中的有效性.
主要方法:
- 进行了一项单一中心的回顾性观察研究.
- 包括2000年1月至2022年12月期间诊断的420名MM患者.
- 患者根据日历时期 (2000-2007,2008-2015,2016-2022) 和移植资格进行了分层.
主要成果:
- 平均存活时间从50.7个月 (2000-2007年) 提高到72.4个月 (2008-2015年).
- 自主干细胞移植 (ASCT) 显著增加了中位数的生存期,达到132.66个月,而没有ASCT则为38.8个月.
- 新型药物类别,包括蛋白酶体抑制剂 (PI) 和免疫调节药物 (IMID),与传统化疗相比,显著改善了OS.
结论:
- 在过去二十年中,MM生存结果的显著改善.
- 较年轻和符合ASCT条件的患者表现出特别增强的生存益处.
- 持续存在的医疗保健差异需要公平获得现代MM疗法和优化管理策略.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.6K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
199
相关概念视频
Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
Comparing the Survival Analysis of Two or More Groups
113
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
113
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Actuarial Approach
50
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
50
Kaplan-Meier Approach
74
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
74
Assumptions of Survival Analysis
81
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
81
